Table of contents
October 2005 Volume 2 No 10
Editorial
Viewpoint
Nomograms for prostate cancer—is their use evidence-based?
462Prostate cancer nomograms are valuable tools for the discussion of treatment options with patients, but their ability to change patient decisions or improve outcomes remains unproven. In this Viewpoint, Alan Stapleton and Carole Pinnock discuss the limitations and uncertainties surrounding these tools, such as changes in source population clinical profiles over time, and parallel changes in the usefulness of prognostic factors.
Research Highlights
Herbal treatments for erectile dysfunction are contaminated with sildenafil and tadalafil
464Neoadjuvant androgen deprivation delays curative radiotherapy
464Minimally invasive treatment of renal cell carcinoma
465Cellular senescence suppresses prostate tumorigenesis in mice
466Novel MRI technique for assessing potential live kidney donors
467Monitoring local prostate cancer recurrence after radiation therapy
467No increased risk of bladder cancer after prostate cancer radiation therapy
467Hormonal function and fertility in survivors of testicular cancer
468Hypertension is more prevalent in men with erectile dysfunction
469Practice Points
Do patients benefit from intact specimen removal during laparoscopic radical nephrectomy?
470Do continent patients with overactive bladder respond to muscarinic receptor antagonists?
472Is brachytherapy an effective treatment for penile carcinoma?
474The Urologic Diseases in America project: an opportunity for introspection
476Short-course or long-course radiotherapy for the palliation of bone metastases?
478Reviews
Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
482There is much debate surrounding the suitability and utility of different prognostic markers in prostate cancer. PSA doubling time (PSADT) has become an important marker in predicting the response to salvage radiotherapy and progression to metastatic disease in men with biochemical failure following local therapy. The methods of calculating PSADT and its use as a prognostic marker are discussed in this review by James Eastham.
doi:10.1038/ncpuro0321 | Full Text | PDF (248K)
Therapy Insight: bladder dysfunction associated with multiple sclerosis
492Multiple sclerosis (MS) is commonly associated with a number of lower urinary tract symptoms (LUTS), the type and severity of which vary with regard to the gender of the patient and the severity of their MS. In their article, Vinay Kalsi and Clare Fowler review the neurologic control of bladder function and the different treatments available to patients with MS who experience LUTS. Unlicensed and possible future treatments are also discussed.
doi:10.1038/ncpuro0323 | Full Text | PDF (262K)
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer
502There are a number of factors that can influence a person's risk of developing cancer. In this review focussing on transitional cell carcinoma of the bladder, Erika Wolff and colleagues discuss the genes and molecular pathways implicated in the development of bladder cancer. Models for both the mechanisms behind bladder carcinogenesis and its progression are presented.
doi:10.1038/ncpuro0318 | Full Text | PDF (231K)
